We check the sentence you actually heard.
Not a vague score for an entire molecule. The claim, outcome, population, route, product, and date stay attached.
PepCurrent is an independent, evidence-first publication covering peptides and the science behind the claims. It is made for people who heard something online and want a useful answer before the internet turns “interesting” into “proven.”
Most peptide sites answer “What does it do?” PepCurrent asks three earlier questions: what exactly was studied, in whom, and does that evidence belong to the product or claim being discussed?
Not a vague score for an entire molecule. The claim, outcome, population, route, product, and date stay attached.
Primary and official sources, evidence limits, cut claims, corrections, and version history remain visible.
Every priority answer says what changed, which source caused it, and what would change the conclusion again.
AI systems may help monitor sources, organize evidence, prepare drafts, and perform a separate verification pass. They do not silently publish medical or regulatory conclusions. One system drafts from the source record; a second system rechecks factual claims against primary sources before a separate manual release action. Material medical, safety, and regulatory pages require that second-system review before indexing.
PepCurrent does not accept peptide-vendor advertising, affiliate commissions, sponsored coverage, clinic referrals, or paid product placement. It does not publish dosing, sourcing, reconstitution, stacks, or personalized recommendations. Read the complete methodology, editorial standards, and disclosures.
The publication is the author. PepCurrent uses a publication byline instead of putting an individual’s personal identity on health-adjacent pages. Accountability lives in dated primary sources, public corrections, version history, a separate source-verification pass, and manual publication gates.
The Peptide Current is published by PepCurrent, an independent publication unaffiliated with pharmaceutical companies, peptide manufacturers, clinics, compounding pharmacies, or sellers. It is currently a free, noncommercial public beta. Advertising, sponsorships, affiliates, paid subscriptions, product rankings, and referral programs are paused.
The public-beta contact surface stays deliberately small. These are the two operational inboxes PepCurrent will maintain:
The newsletter is designed for material evidence and FDA-status changes—not a daily content treadmill.
Join the early list →